This website is for UK and Ireland Healthcare professionals only.

If you are not a healthcare professional in the UK, please click here.

If you are not a healthcare professional in Ireland, please click here.

Eliquis® (apixaban)

Risk Minimisation Information for Healthcare Professionals

Therapeutic indication: Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) with one or more risk factors1,2

Risk factors for stroke in NVAF include prior stroke or transient ischaemic attack, age ≥75 years, hypertension, diabetes mellitus, and symptomatic heart failure (NYHA Class ≥II).

Dosing recommendations

The recommended dose of apixaban is 5 mg taken orally twice daily with water, with or without food. Therapy should be continued long-term (Figure 1).

Figure 1

apixaban 2.5 mg Morning

eliquis apixaban 5 mg

apixaban 5 mg

apixaban 5 mg eliquis Night

eliquis apixaban 5 mg

apixaban 5 mg

For patients who are unable to swallow whole tablets, apixaban tablets may be crushed and suspended in water, or 5% glucose in water (G5W), or apple juice or mixed with apple puree and immediately administered orally. Alternatively, apixaban tablets may be crushed and suspended in 60 mL of water or G5W and immediately delivered through a nasogastric tube. Crushed apixaban tablets are stable in water, G5W, apple juice, and apple puree for up to 4 hours.

Dose reduction

In patients with at least two of the following characteristics: age ≥80 years, body weight ≤60kg, or serum creatinine ≥1.5 mg/dL (133 µmol/L), the recommended dose of apixaban is 2.5 mg taken orally twice daily (Figure 2).

Patients with exclusive criteria of severe renal impairment (creatinine clearance [CrCl] 15–29 ml/min) should also receive apixaban 2.5 mg twice daily (Figure 2).

Figure 2

Criteria for apixaban 2.5 mg twice daily dose

Age ≥80 years

Body weight ≤60 kg

Serum creatinine
≥1.5 mg/dL (133 µmol/L)

At least 2 characteristics

apixaban 2.5 mg tablet apixaban
2.5 mg twice daily

Missed dose

If a dose is missed, the patient should take apixaban immediately and then continue with twice daily intake as before.

Click below for information on use in specific patient populations.

Renal impairment  
Dialysis Not recommended
Renal failure
(CrCl <15 ml/min)
Not recommended
Severe renal impairment (CrCl 15–29 ml/min) Dose reduction to 2.5 mg twice daily
Mild (CrCl 51–80 ml/min) or moderate (CrCl 30–50 ml/min) renal impairment 5 mg twice daily. No dose adjustment required unless the patient fulfils criteria for dose reduction to 2.5 mg twice daily based on age, body weight and/or serum creatinine (refer to dosing section)

This Prescriber Guide is not a substitute for the apixaban Summary of Product Characteristics (SmPC). Please consult the SmPC for full prescribing information.